Takeda and Denali Therapeutics Ventures to combat Neurodegenerative diseases

Takeda Pharmaceuticals and Denali therapeutics asserted that they have collaborated to develop and commercialize up to three specified therapeutic product candidates for neurodegenerative diseases including Alzheimer’s disease entailing Denali’s ATV platform for brain’s persistent exposure to biotherapeutic products.

Emiliangelo Ratti, Head of the Neuroscience Therapy Area at Takeda mentioned: “This partnership further exemplifies Takeda’s continued commitment to developing genetically validated therapies for neurodegenerative diseases through an enhanced portfolio comprised of new modalities.”

Denali CEO Ryan Watts, Ph.D. states “We are impressed with Takeda’s commitment to developing treatments for difficult to treat neurodegenerative diseases and look forward to partnering with them to bring medicines to patients.”

As per the terms of collaboration, Denali will lead early clinical development activities and Takeda will lead late stage clinical development activities. Takeda and Denali will jointly commercialize products in the United States and China, and Takeda will possess exclusive commercialization rights in all other markets. The parties will equally share the global profits.